Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL337213 | 0.98 | CA4 (0.43) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL1767658 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL6442487 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL2466395 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL2706203 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| Potassium Ion SCHEMBL29489145 | 0.96 | CA4 (0.41) | CA4CPT2ACLY | |
| SCHEMBL966173 | 0.94 | CA4 (0.43) | CA4CPT2ACLY | |
| SCHEMBL990294 | 0.94 | CA4 (0.43) | CA4CPT2ACLY | |
| SCHEMBL965645 | 0.94 | CA4 (0.48) | CA4CPT2ACLY | |
| Zinc Ion SCHEMBL2315207 | 0.94 | CA4 (0.43) | CA4CPT2ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118829725-A | Method for producing cells | 莱尔免疫制药公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118804933-A | Method for culturing ROR1 binding protein-expressing cells | 莱尔免疫制药公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118660954-A | Method for culturing immune cells | 莱尔免疫制药公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118451098-A | Method for culturing C-JUN-expressing cells | 莱尔免疫制药公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-117083376-A | Method for culturing cells | 莱尔免疫制药公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-116745405-A | Method for culturing immune cells | 莱尔免疫制药公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-115768879-A | Method for culturing cells | 莱尔免疫制药公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2022003056-A1 | EXTRACT OF HIBISCUS SABDARIFFA AND USE THEREOF FOR IMPROVING THE BARRIER FUNCTION AND PROMOTING THE MOISTURIZATION AND DESQUAMATION OF THE SKIN | L'OREAL (FR) | 2022-01-06 | — | — | WO | disclosed |
| US-7772428-B2 | Creatine hydroxycitric acids salts and methods for their production and use in individuals | Northern Innovations and Formulations (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20080300309-A1 | Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals | NEW CELL FORMULATIONS LTD (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1846368-A4 | CREATINE HYDROXYCITRIC ACIDS SALTS AND METHODS FOR THEIR PRODUCTION AND USE IN INDIVIDUALS | NEW HC FORMULATIONS LTD (CA) | 2008-01-23 | — | — | EP | disclosed |
| EP-1846368-A1 | CREATINE HYDROXYCITRIC ACIDS SALTS AND METHODS FOR THEIR PRODUCTION AND USE IN INDIVIDUALS | New HC Formulations Ltd. (CA) | 2007-10-24 | — | — | EP | disclosed |
| US-20070031526-A1 | Topical Deodorant Compositions Based on Hydroxycitric Acid | BIODERM RESEARCH (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060194877-A1 | Creatine hydroxycitric acids salts and methods for their production and use in individuals | NEW CELL FORMULATIONS LTD. (CA) | 2006-08-31 | — | — | US | disclosed |
| WO-2006081682-A1 | CREATINE HYDROXYCITRIC ACIDS SALTS AND METHODS FOR THEIR PRODUCTION AND USE IN INDIVIDUALS | NEW CELL FORMULATIONS LTD. (CA) | 2006-08-10 | — | — | WO | disclosed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | disclosed |
| US-20040185069-A1 | Hydroxycitric acid derivatives for body slimming and tone firming compositions | GUPTA SHYAM K (US) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194877-A1 | Creatine hydroxycitric acids salts and methods for their production and use in individuals | CKMT1A; CKMT1B, GYS1, PYGM | CA4 1308/4885CPT2 152/4885ACLY 62/4885 |
| US-20080300309-A1 | Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals | CKMT1A; CKMT1B, GYS1, PYGM | CA4 1308/4885CPT2 152/4885ACLY 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.